Bristol Myers Squibb’s Opdivo® (nivolumab) has received two new indications to treat esophageal squamous cell carcinoma (ESCC).

• Under the new indications, Opdivo is approved as a first-line treatment for unresectable advanced or metastatic ESCC in adults, regardless of their PD-L1 status, when used in combination with:
  • Fluoropyrimidine- and platinum-containing chemotherapy, or o Yervoy® (ipilimumab – Bristol Myers Squibb).
• Opdivo is administered via intravenous infusion, with treatment for ESCC continuing until acceptable toxicity or disease progression occur, or up to two years. The recommended dosing for ESCC treatment is:
  • Opvido 240mg every two weeks or 480mg every four weeks when used in combination with fluoropyrimidine- and platinum-containing chemotherapy.
  • Opdivo 3mg/kg of the patient’s body weight every two weeks or 360mg every three weeks when used with Yervoy 1mg/kg every six weeks.